Foundation Fighting Blindness

Foundation Fighting Blindness
Name	Foundation Fighting Blindness
Founded	1971
Founder	Michael Lesser
Type	Nonprofit organization
Headquarters	Columbus, Ohio
Area served	United States; global funding partnerships
Focus	Vision research; retinal degenerative diseases

Foundation Fighting Blindness is an American nonprofit organization dedicated to funding research, fostering clinical development, and advocating for treatments and cures for inherited retinal diseases and other causes of vision loss. Founded in the early 1970s, the organization has supported basic science, translational research, and patient-centered initiatives that connect researchers, clinicians, patients, and industry partners. Through grants, collaboration networks, and public engagement, it has influenced the scientific landscape for conditions such as retinitis pigmentosa, Stargardt disease, and age-related macular degeneration.

History

The organization was established in 1971 by Michael Lesser after he sought resources for retinal degeneration research at a time when few institutions prioritized inherited vision loss. Early activities linked patient communities with researchers at universities and medical centers such as Johns Hopkins University, Massachusetts Eye and Ear, and Harvard Medical School. During the 1980s and 1990s, grant programs expanded, aligning with breakthroughs at institutions including Massachusetts Institute of Technology, Stanford University, and University of Pennsylvania that advanced molecular genetics and retinal cell biology. In the 2000s, partnerships with entities like National Institutes of Health, Foundation for the National Institutes of Health, and biotechnology firms catalyzed translational pipelines. More recently, collaborations with organizations such as Biogen, Spark Therapeutics, Editas Medicine, and clinical centers including Bascom Palmer Eye Institute propelled gene therapy, stem cell, and pharmacologic approaches into human trials.

Mission and Programs

The foundation’s mission emphasizes funding research to prevent, treat, and cure retinal degenerative diseases while empowering affected individuals through education and support. Core programs include investigator-initiated research grants that have funded teams at Columbia University, University of California, San Francisco, University of Iowa, Mayo Clinic, and University of Michigan. Translational initiatives such as consortium-building and pipeline acceleration have connected innovators at Genentech, Novartis, Roche, and academic hubs. Patient-focused programs include support networks, genetic testing awareness campaigns, and resources linking families to specialty centers like Wills Eye Hospital and Kellogg Eye Center, as well as registry efforts coordinated with partners like Global Genes and disease-specific advocacy groups.

Research and Funding

The foundation finances a spectrum of research from basic retinal cell biology to late-stage clinical trials. It has invested in gene discovery efforts that leveraged technologies developed at Broad Institute, Salk Institute, and Cold Spring Harbor Laboratory, contributing to identification of disease-causing mutations in genes studied at University College London and Karolinska Institutet. Funding mechanisms include career development awards for investigators affiliated with Yale School of Medicine, University of Toronto, and King's College London, as well as multi-year grants supporting collaborative networks such as consortiums modeled after cooperative efforts like Human Genome Project-era collaborations. Strategic partnerships with philanthropic entities including Bill & Melinda Gates Foundation and corporate sponsors have helped underwrite large-scale programs, while engagement with regulatory stakeholders like U.S. Food and Drug Administration informs trial design and translational priorities.

Clinical Trials and Therapies

Supported work has accelerated diverse therapeutic modalities into clinical testing: gene replacement and gene editing inspired by research at University of Pennsylvania and Children's Hospital of Philadelphia; antisense oligonucleotide approaches developed alongside groups at University of Oxford and University of Antwerp; stem cell transplantation strategies advanced with teams at Mount Sinai Health System and Cedars-Sinai Medical Center; and neuroprotective and pharmacologic agents evaluated in trials at Johns Hopkins Hospital and Massachusetts General Hospital. The foundation has been instrumental in enabling trials for therapies now associated with companies like Spark Therapeutics, which achieved regulatory milestones influenced by collective research. Adaptive trial designs informed by consults with National Eye Institute experts and data-sharing frameworks akin to European Medicines Agency-level practices have streamlined development pathways.

Advocacy and Public Awareness

Advocacy campaigns aim to raise public and policymaker awareness of retinal diseases through storytelling, legislative engagement, and partnership with media outlets and celebrities. The organization has coordinated awareness events and fundraising campaigns comparable in scale to efforts led by groups such as American Cancer Society and Alzheimer's Association to increase visibility for vision research. It collaborates with patient advocacy networks like Genetic Alliance and National Organization for Rare Disorders to promote genetic testing access, insurance policy discussions, and research participation. Public education works closely with academic centers including Johns Hopkins University and professional societies such as American Academy of Ophthalmology to disseminate clinical guidelines and research updates.

Organizational Structure and Governance

Governance is provided by a board of directors composed of leaders from philanthropy, academia, healthcare, and industry, with executive leadership overseeing scientific programs, development, and communications. Scientific advisory panels draw expertise from investigators at institutions like University of Cambridge, Imperial College London, University of California, Los Angeles, Duke University, and Scripps Research to evaluate grant proposals and set research priorities. Financial oversight follows nonprofit standards practiced by organizations including The Rockefeller Foundation and Ford Foundation, with audit and compliance functions liaising with accounting firms and legal advisers to ensure stewardship. Volunteer patient advisors and family councils contribute lived-experience perspectives, linking the foundation to clinical networks at centers such as Bascom Palmer Eye Institute and Wills Eye Hospital.

Category:Health charities in the United States